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Abstract
Background: A study for pain relief therapy with 188Re-HEDP was done in patients with bone
metastases secondary to breast and prostate cancer.
Materials and Methods: Patients received 1.3 or 2.2 GBq, in single or multiple doses. Platelets,
white and red cells were evaluated during 11 weeks. Pharmacokinetic characterization was done
from blood and urine samples for 5 patients along 24 hours. Urinary excretion was evaluated in
other 16 patients during 6 hours. Bone uptake was estimated as remaining activity in whole body.
Scintigraphic images were acquired at 2 and 24 hs post-administration. Absorbed dose in bone
marrow was estimated with Mirdose3. Analgesics intake and pain score were daily recorded.
Tumour markers (PSA, and Tn-structure) were monitored in 9 patients during 4 to 6 months. Single
doses of low activity (1.3 GBq) were given to twelve patients. Nine patients received multiple doses.
Results: All except one patient had normal levels of platelets, white and red cells. Remaining dose
in blood at 2 hours was 9%. Urinary elimination was 58%. Bone uptake at 24 hours was 43% (mean
value; n = 5). No changes of the haematological parameters were detected along follow-up period.
Pain relief was evidenced by decrease or supression of opioid analgesic and by subjective index. PSA
showed a decrease in prostate cancer patients (n = 4). Tn-structure showed a significant increase
after 4 to 8 months.
Conclusion: Single or multiple dose scheme could be safely used, with administered activity of
188Re-HEDP up to 60 mCi, with low bone marrow absorbed doses.
Background
Cancer is the second more frequent cause of death, after
cardiovascular disease in developed countries. Most of
adult patients with neoplasms will develop skeletal me-
tastases that can lead to progressive pain. The develop-
ment of less toxic but equally effective pain relieving
Published: 21 November 2001
BMC Nuclear Medicine 2001, 1:2
Received: 9 August 2001
Accepted: 21 November 2001
This article is available from: http://www.biomedcentral.com/1471-2385/1/2
© 2001 Savio et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-com-
mercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact info@biomedcentral.comBMC Nuclear Medicine 2001, 1:2 http://www.biomedcentral.com/1471-2385/1/2
agents for bone metastases has been a field of increasing
interest to nuclear medicine [1–6]. In that sense, the ap-
plication of bone-seeking radiopharmaceuticals is a
promising alternative for hemi-body or whole-body radi-
otherapy.
After the successful application of 32P and 89Sr [7–9],
new β - emitter phosphonate radiopharmaceuticals were
developed.
In particular 186Re(Sn) hydroxyethylidene bisphospho-
nate (HEDP) and 153Sm ethylenediaminetetramethyl-
enephosphonic acid (EDTMP) have shown favourable
biodistributions and dosimetries, having thus been ap-
proved for clinical use [10–15]. As 186Re and 153Sm,
188Re emits both beta particles suitable for therapy and a
gamma ray (155 keV), adequate for diagnostic imaging in
order to verify localisation in the pain areas associated to
metastatic process [16–22]. Besides, 188Re may be ob-
tained from a 188Tungsten/188Rhenium generator, re-
sulting in a readily available system for a daily elution
[23–26].
Scintigraphy is the most useful and widely documented
diagnostic tool for detection of bone metastases. It is di-
rectly related to turnover of biochemical markers such as
prostatic acid phosphatase (PAP) and deoxypyrrolidine
(DPD) in urine. Besides, in early stages after administra-
tion of phosphonate radiopharmaceuticals it is not advis-
able to use bone turnover markers. Thus, scintigraphic
evaluation of local action of β  radiation in metastatic tis-
sue plays an important role.
Characterisation of pharmacokinetic behaviour of
188Rhenium-(Sn)-HEDP carried out in a limited number
of patients (n = 5) was applied in the assessment of safety
and therapeutic efficacy of the treatment of painful os-
seous metastases under two levels of administered dose
(35 and 60 mCi; 1.3 and 2.2 GBq) of this radiopharma-
ceutical.
Analgesics intake along a period of time after radiophar-
maceutical administration, following a recorded self es-
timation by the patient associated to scored physical
activities, is a current procedure for evaluation of os-
seous pain relief [27].
Tumour markers have been determined in a group of 9
patients, being Tn structure evaluated in all of them due
to its broad specificity spectrum, while PSA and free PSA
only in those with prostate cancer.
Alterations in carbohydrate profile at cell surface have
been proved in almost all types of cancer [28] influencing
cellular growth [29], invasiveness [30] and metastatic
potential. Monoclonal antibody 83D4 [31] recognizes
specifically the carbohydrate antigen Tn (N acetylgalac-
tosamine O-serine/threonine) expressed in more than
90% of ovaries, endometrium and breast cancers but not
in normal tissues or blood cells [32]. Prostatic specific
antigen (PSA) is secreted by prostate cells into seminal
fluid. Serum levels of total PSA are aberrantly increased
in prostate cancer patients [33], having a very high sen-
sitivity (>85%) and specificity (>90%) as a marker for
that disease.
Single and multiple doses of 188Re-HEDP-both contain-
ing low (35 mCi, 1.3 GBq) and high (60 mCi, 2.2 GBq)
levels of activity doses – were given to a population of 21
patients to assess the possibility of using this scheme
safely and reliably, evaluating haematological follow up,
absorbed dose in bone marrow, tumour markers and an-
algesic intake.
Materials and methods
Materials
Equipment and software
Capintec CRC-12 dose calibrator (CII, USA) was used
with a calibration factor fixed at 496 (×  10). Radioactivity
measurements of chromatographies, blood samples,
plasma and protein precipitate were performed in a NaI
(Tl) Mini Assay Type G-20 gamma counter (Picker,
USA). Scintigraphic images were acquired in a Sophyca-
mmera DSX, 93 PMT, SPECT (SOPHA, France). Multi-
ple regression analysis (MRA) and data processing by
Reglin program [34] was applied for model fitting, as
well as Mirdose3 for dosimetry purposes [35]. Radioac-
tivity measurements of 125Iodine (0.01 kBq-111 kBq)
were done in an automatic well-type gamma counter
(Compact-120 Picker, USA) with a coaxial NaI (Tl) detec-
tor and efficiency of 70%.
Radiopharmaceutical
188Re-HEDP (radiochemical purity > 98%) has been pre-
pared from lyophilised and locally produced kits [36] us-
ing 188Re eluted from a 188W/188Re generator [25,26].
Radiochemical purity was determined by ascending
chromatography with acetone and NaCl 0.9% as mobile
phases and Whatman 1 M and 3 M as stationary phases
respectively.
Protocol
Patients were selected according to the protocol ap-
proved by the Ethical Committee of the University Hos-
pital, Faculty of Medicine, Montevideo, Uruguay. The
criteria for admission of patients to the study were: bone
metastases in patient with cancer; failure of prior con-
ventional therapy (i.e. prostate cancer patients resistant
to therapy with hormones); multiple metastases in bone
scanning, white cells and platelets number higher thanBMC Nuclear Medicine 2001, 1:2 http://www.biomedcentral.com/1471-2385/1/2
4000/mm3 (4 ×  109/litre) and 150.000/mm3 (100 ×  109/
litre) respectively; serum creatinine concentration less
or equal to 1.5 mg/dL (133 µmole/litre). On the other
hand, exclusion criteria were: obstructive renal patholo-
gy or renal insufficiency; urinary incontinence; psychiat-
ric pathology; evidence of spinal marrow compression;
pathological fracture.
Population
Two groups integrated by a total number of twenty-one
patients with painful bone metastases (age: 62 ± 11 years;
13 male and 8 female) were studied after they had pro-
vided written informed consent. Table 1 describes prima-
ry cancer for each patient: prostate (n = 11), breast (n =
7), cervix (n = 1), medullar of the thyroid (n = 1) and un-
known primitive (n = 1). Five of them, who were treated
with radiotherapy which had turned ineffective, partici-
pated in the pharmacokinetic characterisation of the ra-
diopharmaceutical Two patients had a platelet number
less than 150.000/mm3 and short life expectancy.
Methodology
Group I (n = 12) received an intravenous tracer dose fol-
lowed by a therapeutic dose 24 hours later, both admin-
istered as a bolus (1 – 2 mL). The maximum accumulated
dose was set at 35 mCi (1295 MBq), considering radia-
tion safety as well as reasonable expectancy of therapeu-
tic benefit.
The second group (n = 9, Group II) participated in a
scaled dose protocol with a proposed dose of 60 mCi
(2220 MBq) for a 40% bone uptake.
Five patients from Group I, who participated of pharma-
cokinetic characterisation of the radiopharmaceutical,
were hospitalised and remained 24 hours after therapeu-
tic dose administration for control and sample collec-
tion. Pre-hydration was not performed.
Image acquisition
Scintigraphic images were acquired immediately and 24
hs after first dose administration. Lesion to normal bone
ratio was determined in selected metastases.
Blood sampling and urine collection
Blood samples were drawn from an antecubital vein op-
posite to the injection site at preset intervals (2, 4, 8, 12,
30 min, and 1, 2, 4, 6, 12 and 24 hs post-injection) with
heparinised syringes in the 5 patients of Group I, subject
to pharmacokinetic characterisation. Also total urine
was collected at time intervals (0–1, 1–2, 2–4, 4–6, 6–12,
12–18 and 18–24 hours). In the other group (n = 16) only
urine collection until 6 hours (0–1, 1–2, 2–4, 4–6 hs) was
performed and 24 hours excretion was estimated. Cath-
eterization was done to facilitate sample collection and
minimize possible contamination, as well as to diminish
bladder wall irradiation due to urinary retention.
Blood analysis for compartmental distribution of radiopharmaceuti-
cal
A volume of 1 mL of blood was measured for total activi-
ty. Plasma was separated by centrifugation. Trichloro-
acetic acid (TCA) for protein precipitation was added to
plasma and centrifuged during 5 minutes. Measure-
ments of activity present in blood, plasma, TCA superna-
tant and precipitate were done.
Table 1: Patient clinical characteristic.
Patient Age (years) Sex Cancer
1 70 M Prostate
2 76 M Prostate
3 56 M Prostate
4 68 M Prostate
5 65 M Prostate
6 74 M Prostate
7 61 M Prostate
8 65 M Prostate
96 6 F B r e a s t
10 34 F Breast
11 42 F Cervix
12 51 F Breast
13 69 F Breast
14 72 M Unknown primitive cancer
15 64 F Breast
16 62 M Prostate
17 62 M Prostate
18 74 M Medullar Thyroid
19 54 M Prostate
20 77 F Breast
21 50 F Breast
mean value ± standard deviation = 62 ± 11 years
Table 2: Protein binding values
Time (h) mean value ± s.d.
0.08 44 ± 12
0.60 46 ± 12
1.00 48 ± 12
2.00 53 ± 14
6.00 62 ± 12
12.0 69 ± 11BMC Nuclear Medicine 2001, 1:2 http://www.biomedcentral.com/1471-2385/1/2
Urine excretion
Total recovered volume of urine was measured and aliq-
uots of 20 mL were assayed for radioactivity in dose cal-
ibrator. Suitable corrections were introduced for
physical decay.
Data processing and pharmacokinetics modelling
Whole blood volume was estimated on the basis of pa-
tient weight and height.
Multiple regression analysis of blood and plasma profiles
was performed. Calculation of microconstants (π ,α ,β )
were obtained by model fitting (Table 23) [37].
Elimination constant (ke) was calculated from urine pro-
files by:
ln (1 - E/Ao) = -ko t, where E is urine activity at time t and
Ao is the administered dose. Bone uptake was estimated
as remaining dose at 24 hours, by Ao - Emax, where A0 is
the 188Re-HEDP administered dose and Emax is total ac-
cumulated urine excretion.
Haematological follow-up
Number of platelets and white and red cells were weekly
controlled during 11 weeks.
Tumour markers
Prostatic specific antigen (PSA) was evaluated in 6 male
patients, 5 with prostate cancer and one with thyroid
cancer. Tn structure was evaluated in 8 patients: pros-
tate cancer (n = 5), breast cancer (n = 2), thyroid cancer
(n = 1).
PSA determination was done with locally produced im-
munoradiometric assay (IRMA) consisting in two mono-
clonal antibodies, specific for the exposed epitope of the
PSA molecule, one as capture antibody and the other as
tracer upon labelling with 125I by limiting chloramine-T
method [38].
Tn structure was evaluated by an homologous IRMA as-
say locally produced using a specific antibody 83D4 of
the type IgM immobilised to a solid phase. As standard a
Tn-rich mucin was used and the complex was detected by
means of the 83D4 labelled with 125I.
Therapeutic response evaluation
Patients were given a form for daily self-evaluation and
record of pain (scaled between 0 and 5), physical activity
and analgesic administration (amount and kind of drug).
Dosimetry
Residence time in trabecular bone was considered equal
to that in cortical bone, and calculated as follow:
Residence time = (0.5 ×  C/A ×  1.443 ×  16.9) h
C – Bone uptake (mCi)
A – Dose administered (mCi)
16.9 – t1/2 of 188Re
Dose absorbed to bone marrow was calculated using
Mirdose Version 3.0, introducing residence time values
calculated as described above.
Results
188Re-HEDP was labelled with a radiochemical purity
higher than 99% and showed an in-vivo profile similar to
99mTc-HEDP, with a clearance of 70% within the first 6
hours and a bone uptake of 10 to 70%.
Figure 1 shows a typical blood and plasma activity con-
centration profile for one patient, following the thera-
Table 3: Phases constants in a three compartment model for 
188Re-HEDP for blood and plasma samples.
Phase constant Blood*(h) Plasma*(h)
π 0.14 ± 0.16 0.12 ± 0.11
α 1.5 ± 0.7 1.3 ± 0.8
β 15 ± 8 21 ± 8
* mean value ± standard deviation, n = 5
Figure 1
Blood and plasma profiles after 188Re-HEDP administrationBMC Nuclear Medicine 2001, 1:2 http://www.biomedcentral.com/1471-2385/1/2
peutic dose. Radiopharmaceutical binding to blood cells
was less than 8%.
Protein binding at five minutes after administration was
(44  ± 12)%, while 26% of the injected dose (I.D.) re-
mained in blood, and increased to (69 ± 11)% at twelve
hours (3 % of the I.D. remained in blood), as it is shown
in Table 32. In one patient whose hematocrit value was
below 20%, protein binding percentage was initially 75%
(38% of the I.D.) and raised to almost 90% at twelve
hours (2% of the I.D.). This fact was also previously re-
ported for 186Re-HEDP, attributing to a possible in vivo
decomposition leading to compounds having a different
plasma protein binding [22].
Figure 2 shows the blood clearance as a function of time
(percentage of remaining dose of tracer and therapeutic
administrations) and accumulated excreted urine as per-
centage of administered dose versus time. No statistical
differences were observed between both administra-
tions. Similar blood clearances are observed for both
dose administrations. A three compartment model was
the best fit for the five patients and the corresponding
half-lives to each phase are shown in Table 23. A dispo-
sition phase (π ) that took place during the first 30 min-
utes post administration was verified, followed by a
disposition phase (α ) calculated from (17± 4)% to (9 ±
2)% of the I.D. (between 30 minutes and 2 hours). Final-
ly, the elimination phase (β ) took place from (5 ± 1)% to
(2 ± 1)% of the I.D., estimated from 6 to 24 hours post-
administration curve.
Urine profile showed that (58 ± 15) % of I.D. was elimi-
nated in 24 hours, being its 70% collected along the first
6 hours post-administration. Table 4 shows renal elimi-
nation (t1/2) for these patients.
Table 5 shows bone uptake, bone marrow dose per activ-
ity unit administered (corrected to a weight of 70 kg) and
total bone marrow dose are represented in Table 5, after
single or multiple 188Re-HEDP administration (Group I
and II). A great variability in bone uptake was verified
(44 ± 18% in Group I; 31 ± 18% in Group II). Neverthe-
less, maximum total absorbed dose to bone marrow was
similar for both groups, having received a mean value of
31 or 55 mCi (1147 or 2035 MBq). On the other hand,
while all the patients received 0.29–1.18 mCi/kg (10.7–
43.7 MBq/kg), dosimetry estimations showed that high-
er bone uptake correlated with higher absorbed doses to
bone marrow. Biochemical parameters (number of
platelets, white and red cells variation during a time in-
terval of 11 or 24 weeks (single or multiple dose) are
shown in Figure 3, for representative patients of each
Figure 2
Blood clearance (after tracer and therapeutic dose) and renal
excretion for a group of five patients, who were adminis-
tered 35 mCi (1295 MBq) of 188Re-HEDP
Figure 3
Haematological parameters in two patients who received 35
or 60 mCi (1295 or 2220 MBq) of 188Re-HEDP (single and
multiple dose respectively) vs. timeBMC Nuclear Medicine 2001, 1:2 http://www.biomedcentral.com/1471-2385/1/2
group (patient 8 – Group I and patient 17 – Group II).
Only two patients, whose initial platelet number was
lower than recommended by the acceptance limit,
showed a significant decrease respect the others. The
overall platelet decrease found in the fourth week after
dose administration, which correspond to the minimum
values, was of (18 ± 3)% in Group I and (29 ± 4)% in
Group II, being the difference between both groups sta-
tistically significant (p < 0.001). No variations of red and
white cells were observed because of 188Re-HEDP treat-
ment.
Pain evaluation, measured by subjective index for 18 pa-
tients, is shown in Table 6. Seventy eight per cent of these
patients (n = 14) recognized a decrease of 60% of the in-
itial pain, compared to the status previous to receiving
the therapeutic dose of 188Re-HEDP. Two patients (11%)
experimented a pain increase and another two found no
change. A decrease of 62% is reported in analgesic drug
treatment for 14 cases (78%); it remained as before
188Re-HEDP treatment in 3 patients (17%) and was in-
creased in one of them (5%).
Opiates were used in 14 patients (78%); intake was de-
creased in 8 patients (57%) and totally abandoned in the
rest.
In those patients who referred an initial good pain relief,
a second dose was administered with an elapsed time of
three to four months from the first one. Dosimetric eval-
uation (see Table 5) also showed a safe profile protocol.
Three doses were administered to only one patient, with
a good quality of life.
With reference to tumour markers, four patients pre-
sented increased PSA serum levels (140 ± 23 ng/mL)
previous to the first 188Re-HEDP administration, one
patient showed a slightly high level (7.2 ng/mL) and one
patient (thyroid disease) was in the normal range (1.4
ng/mL). The follow-up showed that the four patients
with PSA initially high, lowered their values in a ratio of
2.3 ± 0.7 respect to first determinations. In the second
situation, there was no decrease in serum values, which
remained in 15.5 ± 3 ng/mL during almost 4 months af-
ter administration of radiopharmaceutical. The patient,
in the normal range, remained unchanged with a mean
value of 1.5 ± 0.5 ng/mL during 8 months.
About Tn structure, initial values were low in 7 patients
(3 ± 2 ng/mL) and very elevated in one breast cancer (74
ng/mL). The follow-up of patients with initial low Tn val-
ues showed an increase of more than 54 ng/mL, which
appeared after 4 to 8 months of administration of first
treatment.
Discussion
188Re-HEDP was labelled with a radiochemical purity
higher than 99% and showed an in-vivo profile similar to
99mTc-HEDP, with a fast clearance and a high variability
in bone uptake.
Blood clearance profiles were also similar to those re-
ported for 99mTc-HEDP [39], except for long times
where higher values were determined for 188Re-HEDP
(5% of I.D. after 12 hs post-administration).
The clinical results included evaluation of radiopharma-
ceutical toxicity that could be evidenced by the variation
in haematological parameters (platelet, white and red
blood cell count) and changes in pain and drug intake.
All of these were measurable parameters, except changes
in pain which were subjectively appreciated by the pa-
tients themselves. The chosen approach of self-assess-
ment by a conventional scale was adequate, providing a
reasonable understanding of the situation by the pa-
tients.
Haematological evaluation showed that platelets were
the most sensitive element. A decrease in the number of
platelets was observed in every dose. Nevertheless, only
two patients arrived to an abnormal platelet count, and
these were patients whose former blood element count
was out of the admission parameters and were given a
dose because it was the only pain relief alternative that
could be offered. In spite of the low platelet count, no
bleeding were evident and it was verified a clear pain re-
lief. Overall decrease of platelet counting, even in the
more pronounced cases, remained in levels that did not
affect the evolution of the patient. Patients receiving
higher doses (Group II) were affected by a more pro-
nounced decrease in platelet counting respect to the low-
er dose group (Group I).
With reference to white cell counting the decrease ob-
served in the first period (four weeks) was recovered by
Table 4: Renal elimination t1/2 after therapeutic dose 
administration.
Patient t1/2 (hrs)
AP 10.5
HL 5.1
FC 9.1
NR 7.3
TD 5.0
mean value ± s.d. 4.4 ± 3.5BMC Nuclear Medicine 2001, 1:2 http://www.biomedcentral.com/1471-2385/1/2
the increase in the remaining period of seven weeks. All
variations found were values within the normal range,
except in the two patients already described. No signifi-
cant deviation was detected in the red blood cells param-
eter.
We found that patients with low hematocrit had high
protein binding. This phenomenon was also reported
previously for 186Re-HEDP, and was attributed to a pos-
sible in vivo decomposition leading to compounds hav-
ing a different plasma protein binding [22]. Absorbed
dose estimations for bone marrow were similar to those
reported by Maxon et al (40) for both groups as it is
shown in Table 7.
Table 5: Dosimetric estimations for absorbed doses after single or multiple 188Re-HEDP administration, with two levels of activity
Patient Adm. Dose Weight Adm.Dose/kg Bone Uptake Res.Time B.M.D. TBMD TBMD/w
mCi kg kg (%) hrs rad/mCi rad rad
Group I
1 L.H. 41,6 88,2 0,47 59 7,2 3,04 126,46 159,3
2 G.M 35,3 61 0,58 68,7 8,4 3,54 124,96 108,9
3 A.P 33,09 75 0,44 65,4 8 3,38 111,84 119,8
4 J.P. 34,8 80 0,44 43,5 5,3 2,24 77,95 89,1
5 E.S 30,7 62 0,5 63,6 7,8 3,29 101 89,5
6 F.C 30,7 67 0,46 43,7 5,3 2,24 68,77 65,8
7 S.V. 24,4 83 0,29 46,9 5,7 2,4 58,56 69,4
8 H.L 26,7 68 0,39 39,6 4,8 2,03 54,2 52,7
9 N.R 25,5 62 0,41 38,5 4,7 1,98 50,49 44,7
10 G.F 27,5 57 0,48 25,2 3,1 1,31 36,03 29,3
11 T.D. 19,4 65,5 0,3 25,3 3,1 1,31 25,41 23,8
12 B.B. 38,7 92 0,42 10,1 1,2 0,51 19,74 25,9
mean 31 72 0,43 44 5,4 2,3 71 73
s.d. 6 12 0,08 18 2,2 0,9 37 42
Group II
13 D.R. 65,9 77 0,86 33,4 4,1 1,73 114,01 124,8
14 APC 60 60 1 41,2 5 2,11 126,6 108,5
15 M.M 38,3 62 0,62 36,6 4,5 1,9 72,77 64,5
M.M 27 62 0,44 47,1 5,7 2,4 64,8 57,4
16 J.F. 64,7 86 0,75 27,7 3,4 1,43 92,52 113,7
J.F. 63 85 0,74 55,1 6,7 2,83 178,29 216,5
17 E.V. 42,5 93 0,46 39,8 4,9 2,07 87,98 116,9
E.V. 72,9 92 0,79 12,6 1,5 0,63 45,93 60,4
18 C.B. 76,8 68 1,13 15,5 1,9 0,8 61,44 59,7
C.B. 61,9 62 1 14 1,7 0,72 44,57 39,5
19 G.R. 63 60 1,05 53,4 6,5 2,74 172,62 148
G.R. 54,9 60 0,92 64,7 7,9 3,33 182,82 156,7
20 E.U. 33,2 60 0,55 23 2,8 1,18 39,18 33,6
E.U. 35,2 60 0,59 36,1 4,4 1,87 65,82 76,8
21 A.L. 82,9 70 1,18 7,5 0,9 0,38 31,5 31,5
A.L. 44,3 70 0,63 7,5 0,9 0,38 16,83 16,8
A.L. 41,1 70 0,59 7,5 0,9 0,38 15,62 15,6
mean 55 70 0,78 31 3,7 1,6 83 85
s.d. 17 12 0,23 18 2,2 0,9 55 56
Res. Time – Residence Time BMD – Bone Marrow Dose TBMD – Total Bone Marrow Dose TBMD/w – Total Bone Marrow Dose/weightBMC Nuclear Medicine 2001, 1:2 http://www.biomedcentral.com/1471-2385/1/2
Patients evaluated for PSA (free and total) and Tn are not
statiscally conclusive due to the low number of cases.
Nevertheless we consider important to evaluate these
markers since the beginning of radiopharmaceutical
therapy. In our observation there was an association be-
tween increased level of tumour markers and the onset of
analgesic and pain as well as impaired physical activity.
Pain decrease was observed in 81% of the patients after
administration of the therapeutic dose. In a 16.6% of
these cases, relief was total. In the rest of the patients
overall relief was approximately half (54%) of the initial
score of pain. Seventy five per cent of patients belonging
to Group I started the pain relief between the first and
second week after dose administration, maintaining this
effect until 3 to 6 weeks. Patients from Group II showed
an earlier response to treatment, reducing the pain dur-
ing the first week post-injection with a longer duration of
the response up to 16 weeks in one case. Our results are
in accordance to those reported by Palmedo et al (40),
even though higher pain palliation response was ob-
tained in our case for both levels of activity administered.
Conclusion
We can conclude that 188Re-HEDP can be safely admin-
istered in the conditions of the above described protocol.
Being bone marrow the critical organ for absorbed dose,
estimated values were similar to those reported for other
bone therapeutic radiopharmaceuticals in clinical use.
The first administered dose (at tracer level) has an im-
portant role for evaluation of bone uptake and estima-
tion of bone marrow absorbed dose in order to
individualise the whole therapeutic scheme for each pa-
tient.
Residence times was an important parameter evaluated
through urinary elimination of the radiopharmaceutical.
Although the second group of patients (2.2 GBq) re-
ceived double administered activity, absorbed doses
were highly dependent of bone uptake percentage. Sev-
enty eight per cent of the patients reported an improved
quality of life in terms of pain relief, reduction of analge-
sic intake and/or daily activity.
This study involved a small population, which does not
allow detection of significant differences regarding pain
relief degree and duration in different administered ac-
tivities or multiple vs single doses, because of sample
number. Nevertheless, it is a clear conclusion that higher
level of administered dose or multiple doses were safe
and well tolerated according to tested protocol.
List of abbreviations used
188Re-HEDP 188Re-hydroxyethylidene diphosphate
PSA prostatic specific antigen
153Sm-EDTMP etylendiaminetetramethylenephosphon-
ic acid
PAP prostatic acid phosphatase
DPD deoxypyrrolidine
TCA trichloroacetic
IRMA immnunoradiometric assay
I.D. injected dose
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